Could a simple blood test replace the biopsy for prostate cancer?

NCT ID NCT07144228

Recruiting now Diagnosis Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood test called HeLP™ that looks at proteins in platelets to diagnose prostate cancer. Researchers want to see if it can be a safe and accurate alternative to current tests like PSA, MRI, and biopsy. The study will enroll 300 men suspected of having prostate cancer and compare the test results with standard methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HeLP™ blood test (platelet proteomic assay)
What this could lead to: If successful, this could provide a simpler, less invasive way to diagnose prostate cancer and assess its severity, potentially reducing the need for biopsies.
What could go wrong: This is an early-stage validation study with 300 participants. The test may not prove accurate enough to replace current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (DIAGNOSIS)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.